title: Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japan.
abstract: OBJECTIVE
  To evaluate association of clinical remission at month 6 with functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis (RA).
  
  
  METHODS
  This 12-month prospective, multicenter cohort study enrolled 168 patients with RA who started abatacept. Outcomes were assessed using composite measures, quality of life indices, and the van der Heijde-modified total Sharp score (mTSS). The logistic regression analysis was applied to identify factors associated with outcomes and their odds ratios (OR) with 95% confidence interval (95% CI).
  
  
  RESULTS
  At month 6 and 12, 21.4% and 26.2% of the patients achieved Simplified Disease Activity Index (SDAI) remission (SDAI <3.3), and 40.6% and 41.7% achieved Health Assessment Questionnaire-Disability Index (HAQ-DI <0.5) remission. Among 129 patients whose mTSS progression was evaluated at month 12, 83 (64.3%) achieved structural remission (ΔmTSS ≤0.5 for 12 months). SDAI remission at month 6 was identified as a significant predictor of both functional (OR, 3.732; 95% CI, 1.328-10.489) and structural remissions (OR, 4.301; 95% CI, 1.298-14.243) at month 12 after adjusting for covariates.
  
  
  CONCLUSIONS
  Aiming for SDAI remission at month 6 is an appropriate strategy to obtain good functional and structural outcomes at month 12.
authors.affiliation: a Department of Pharmacovigilance and.|b Department of Rheumatology, Graduate School of Medical and Dental Sciences , Tokyo Medical and Dental University (TMDU) , Tokyo , Japan.
authors.forename: Hayato
authors.initials: H
authors.lastname: Yamazaki
authors.affiliation: a Department of Pharmacovigilance and.|b Department of Rheumatology, Graduate School of Medical and Dental Sciences , Tokyo Medical and Dental University (TMDU) , Tokyo , Japan.
authors.forename: Fumio
authors.initials: F
authors.lastname: Hirano
authors.affiliation: c Division of Rheumatology, Department of Internal Medicine , Keio University School of Medicine , Tokyo , Japan.
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Takeuchi
authors.affiliation: d Department of Rheumatology/Clinical Immunology , Saitama Medical Center, Saitama Medical University , Kawagoe , Japan.
authors.forename: Koichi
authors.initials: K
authors.lastname: Amano
authors.affiliation: c Division of Rheumatology, Department of Internal Medicine , Keio University School of Medicine , Tokyo , Japan.
authors.forename: Jun
authors.initials: J
authors.lastname: Kikuchi
authors.affiliation: a Department of Pharmacovigilance and.|b Department of Rheumatology, Graduate School of Medical and Dental Sciences , Tokyo Medical and Dental University (TMDU) , Tokyo , Japan.
authors.forename: Mari
authors.initials: M
authors.lastname: Kihara
authors.affiliation: b Department of Rheumatology, Graduate School of Medical and Dental Sciences , Tokyo Medical and Dental University (TMDU) , Tokyo , Japan.
authors.forename: Waka
authors.initials: W
authors.lastname: Yokoyama
authors.affiliation: e Tokyo Metropolitan Geriatric Hospital , Tokyo , Japan.
authors.forename: Takahiko
authors.initials: T
authors.lastname: Sugihara
authors.affiliation: f Ome Municipal General Hospital , Tokyo , Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Nagasaka
authors.affiliation: g Yokohama City Minato Red Cross Hospital , Yokohama , Japan , and.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Hagiyama
authors.affiliation: h Tokyo Kyosai Hospital , Tokyo , Japan.
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Nonomura
authors.affiliation: a Department of Pharmacovigilance and.|b Department of Rheumatology, Graduate School of Medical and Dental Sciences , Tokyo Medical and Dental University (TMDU) , Tokyo , Japan.
authors.forename: Ryoko
authors.initials: R
authors.lastname: Sakai
authors.affiliation: a Department of Pharmacovigilance and.|b Department of Rheumatology, Graduate School of Medical and Dental Sciences , Tokyo Medical and Dental University (TMDU) , Tokyo , Japan.
authors.forename: Michi
authors.initials: M
authors.lastname: Tanaka
authors.affiliation: a Department of Pharmacovigilance and.|b Department of Rheumatology, Graduate School of Medical and Dental Sciences , Tokyo Medical and Dental University (TMDU) , Tokyo , Japan.
authors.forename: Ryuji
authors.initials: R
authors.lastname: Koike
authors.affiliation: a Department of Pharmacovigilance and.|b Department of Rheumatology, Graduate School of Medical and Dental Sciences , Tokyo Medical and Dental University (TMDU) , Tokyo , Japan.
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Nanki
authors.affiliation: b Department of Rheumatology, Graduate School of Medical and Dental Sciences , Tokyo Medical and Dental University (TMDU) , Tokyo , Japan.
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kohsaka
authors.affiliation: b Department of Rheumatology, Graduate School of Medical and Dental Sciences , Tokyo Medical and Dental University (TMDU) , Tokyo , Japan.
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Miyasaka
authors.affiliation: a Department of Pharmacovigilance and.|b Department of Rheumatology, Graduate School of Medical and Dental Sciences , Tokyo Medical and Dental University (TMDU) , Tokyo , Japan.
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Harigai
mesh_terms: D000069594:Abatacept / Q000627:therapeutic use*; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology / Q000523:psychology; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D011788:Quality of Life; D012074:Remission Induction / Q000379:methods; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D000069594:Abatacept
keywords: Abatacept; Outcome assessment; Remission; Rheumatoid arthritis